Ocular Therapeutix said its chief strategy officer is leaving for a CEO job at a private company. The filing names no replacement or change to company plans, so it does not show a changed outlook.
The notice leaves Ocular without its chief strategy officer as of October 16. It names no replacement and reports no change to company plans or work, so it does not show a changed outlook on its own.
Follow Ocular Therapeutix, Inc. (OCUL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OCUL